Our Vision | Innovative Drug Development2018-11-08T09:50:11+00:00

Our Vision at Alzheon

We strive to bring transformational therapies to patients.

We are passionately dedicated to developing effective treatments for Alzheimer’s disease and other devastating neurodegenerative disorders.

We are applying innovation to drug development in neurodegeneration by capitalizing on scientific and clinical insights, so we can rapidly and efficiently  move towards new therapeutic solutions with substantially lower development risk.

We are committed to improving the lives of patients, their families and caregivers.

We aim to develop breakthrough therapies that can change the lives of patients with neurodegenerative disorders.

Our Approach

Our Precision Medicine Approach in Alzheimer’s

Right Patients:  APOE4/4 early to mild Alzheimer’s

  • Homogeneous population overexpressing amyloid pathology
  • Focus on early to mild Alzheimer’s where amyloid oligomers play key role in disease progression 

Right Drug:
Improved ALZ-801 oral prodrug formulation

  • Consistent plasma levels provide for high brain penetration for amyloid oligomer inhibition
  • Improved oral absorption & GI tolerability
  • No vasogenic brain edema in tramiprosate clinical trials 

Right Trial: 
Phase 2b trial to confirm clinical efficacy in APOE4/4 Alzheimer’s disease patients

  • Phase 3 program authorized by FDA with validated cognitive & functional measures
  • Well tolerated, long-term safety evaluated in 2,000 patients at effective clinical dose
  • FDA agreed to use tramiprosate safety data for ALZ-801 NDA submission
  • Fast Track designation granted for ALZ-801 Alzheimer’s program

For Patients and Caregivers

We are not yet enrolling patients in our Phase 2b clinical trial with ALZ-801.

Please check back as we will update our website when we are ready to start our clinical trial.